C

China Resources Pharmaceutical Group Ltd
HKEX:3320

Watchlist Manager
China Resources Pharmaceutical Group Ltd
HKEX:3320
Watchlist
Price: 5.57 HKD 1.27% Market Closed
Market Cap: 35B HKD
Have any thoughts about
China Resources Pharmaceutical Group Ltd?
Write Note
China Resources Pharmaceutical Group Ltd
/
Balance Sheet
/
Current Portion of Long-Term Debt

China Resources Pharmaceutical Group Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Pharmaceutical Group Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Current Portion of Long-Term Debt
HK$54.5B
CAGR 3-Years
-4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Current Portion of Long-Term Debt
HK$2.5B
CAGR 3-Years
30%
CAGR 5-Years
6%
CAGR 10-Years
4%
U
United Laboratories International Holdings Ltd
HKEX:3933
Current Portion of Long-Term Debt
¥1B
CAGR 3-Years
-9%
CAGR 5-Years
-23%
CAGR 10-Years
-14%
Sino Biopharmaceutical Ltd
HKEX:1177
Current Portion of Long-Term Debt
¥8.5B
CAGR 3-Years
66%
CAGR 5-Years
60%
CAGR 10-Years
64%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Current Portion of Long-Term Debt
¥3.3B
CAGR 3-Years
2%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
35B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
16.42 HKD
Undervaluation 66%
Intrinsic Value
Price
C
What is Intrinsic Value?

See Also

What is China Resources Pharmaceutical Group Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
54.5B HKD

Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Current Portion of Long-Term Debt amounts to 54.5B HKD.

What is China Resources Pharmaceutical Group Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
3%

Over the last year, the Current Portion of Long-Term Debt growth was -4%. The average annual Current Portion of Long-Term Debt growth rates for China Resources Pharmaceutical Group Ltd have been -4% over the past three years , 3% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.